Lexeo Therapeutics, Inc. 8-K

What Happened
On May 11, 2026, Lexeo Therapeutics, Inc. issued a press release announcing business highlights and its financial results for the quarter ended March 31, 2026 (reported under Item 2.02 of Form 8-K). The company also posted an updated corporate presentation on its website, which it will use in investor and analyst meetings. The press release and presentation were furnished as Exhibits 99.1 and 99.2 to the Form 8-K, respectively; the report was signed by CEO R. Nolan Townsend.

Key Details

• Filing date: May 11, 2026 (Form 8-K).
• Results covered: Quarterly results for the three months ended March 31, 2026 (Item 2.02 – earnings/financial results).
• Exhibits: Press release (Exhibit 99.1) and updated Corporate Presentation dated May 2026 (Exhibit 99.2) were furnished/incorporated by reference.
• Corporate Presentation will be used in investor/analyst meetings and is posted on the company website.

Why It Matters
This filing provides investors with Lexeo’s latest quarterly results and the company’s current messaging to the market. Review the attached press release and corporate presentation for specific revenue, expense, cash position, and operational updates to assess near-term performance and strategy.